Identification of cells of leukemic stem cell origin with non-cell autonomous regenerative properties. Hollands CG, Boyd AL, Zhao X, Reid JC, Henly C, Elrafie A, Boylan D, Broder E, Kalua O, Johnson P, Mark A, McNicol J, Xenocostas A, Berg T, Foley R, Trus M, Leber B, Garcia-Horton A, Campbell C, Bhatia M. Cell Rep Med. 2024 Apr 16;5(4):101485. Doi: 10.1016/j.xcrm.2024.101485. Epub 2024 Apr 5.

The successful management of acute promyelocytic leukemia during pregnancy: A case report. Salter B, Radford M, Berg T, Leber, B. Leuk Lymphoma. 2024 Apr;65(4):526-529. Doi: 10.10180/10428194.2023.2295786. Epub 2023 Dec 19.

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, Mekhaeil B, Singh K, Menjolian G, Farrell T, Abdulkarim B, Sur RK, Mesci A, Ellis P, Berg T, Bramson JL, Muti P, Steinberg GR, Tsakiridis T. Mol Oncol. 2023 Nov 17;17(11):2235-2256. DOI: 10.1002/1878-0261.13508.

PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Alshamleh I, Kurrle N, Makowka P, Bhayadia R, Kumar R, Süsser S, Seibert M, Ludig D, Wolf S, Koschade SE, Stoschek K, Kreitz J, Fuhrmann DC, Toenges R, Notaro M, Comoglio F, Schuringa JJ, Berg T, Brüne B, Krause DS, Klusmann JH, Oellerich T, Schnütgen F, Schwalbe H, Serve H. Leukemia. 2023 Dec;37(12):2367-2382. DOI: 10.1038/s41375-023-02041-5. Epub 2023 Nov 7.

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, Wang S, Singh K, Menjolian G, Farrell T, Mesci A, Liu S, Berg T, Bramson JL, Steinberg GR, Tsakiridis T. Commun Biol. 2023 Sep 8;6(1):919. DOI: 10.1038/s42003-023-05289-w. Epub 2023 Sep 8.

Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Boyd AL, Lu J, Hollands CG, Alsostovar L, Murali S, Reid JC, Ye W, Vandersluis S, Johnson P, ElRafie A, Porras DP, Xenocostas D, Leber A, Leber B, Foley R, Trus M, Berg T, Kawata E, Xenocostas A, Bhatia M.  Cell Rep Med. 2023 Jul 18;4(7):101108. DOI: 10.1016/j.xcrm.2023.101108. Epub 2023 Jul 10.

LSD1 inhibition modulates transcription factor networks in myeloid malignancies. Hartung E, Singh K, Berg T. Frontiers in Oncology-Hematologic Malignancies. 10 Mar 2023; 13;1-13. DOI: 10.3389/fonc.2023.1149754.

Cardiovascular Events among Recipients of Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis. Aghel N, Lui M, Wang V, Khalaf D, Mian H, Hillis C, Walker I, Leber B, Lipton J, Aljama M, Lepic K, Berg T, Garcia-Horton A, Petropoulos JA, Masoom H, and Leong DP. Bone Marrow Transplant. 2023 Feb 27;58:478-490. DOI: 10.1038/s41409-023-01928-2.

A retrospective cohort study of donor cell leukemia. Salter B, Raslan O, Demczuk S, Leber B, Garcia-Horton A, Walker I, Berg T, Butcher D, Lepic KL, McCready E, Wasi P, Khalaf D. ASH 2022.  Blood. 15 Nov 2022;140(Suppl.1): 12916-12917. DOI: 10.1182/blood-2022-164643

Review: Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia. Yan Y, Upadhyaya R, Zhang VW, Berg T. Exp Hematol. 2022 May 1;109:P1-10.E1. Epub 2022 Mar 12. DOI: 10.1016/j.exphem.2022.03.003.

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses. Tsakiridis EE, Broadfield L, Marcinko K, Biziotis OD, Ali A, Mekhaeil B, Ahmadi E, Singh K, Mesci A, Zacharidis PG, Anagnostopoulos AE, Berg T, Muti P, Steinberg GR, Tsakiridis T.  Transl Oncol. 2021 Aug 31;14(11):101209. DOI: 10.1016/j.tranon.2021.101209.

Proteomic Analysis Reveals Autism-Associated Gene DIXDC1 Regulates Proteins Associated with Mitochondrial Organization and Function. Kwan V, Rosa E, Xing S, Murtaza N, Singh K, Holzapfel N, Berg T, Lu Y, Singh KK. J Proteome Res. 2021 Jan 1;20(1):1052-1062. DOI: 10.1021/acs.jproteome.0c00896.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, Wollmer E, Wasch R, Bornhauser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kroger N, Wolschke C, Schleuning M, Gotze KS, Schmid C, Crysandt M, Ebeling E, Wolf D, Wang Y, Bohm A, Thiede C, Haferlach T, Michel C, Bethge W, Wundisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK.  J Clin Oncol. 2020 Sep 10;38(26):2993-3002.

Editorial: Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplants and Lymphoma. Berg T, Mian HS, Meyer RM. JAMA Oncol. 2020 Jul 1;6(7):989-991.

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, Wagner SA, Lübbert M, Jung M, Serve H, Schüle R, Berg T.  Leukemia. 2019 Jun 24;33(6):1411-1426.

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia. Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP. Haematologica. 2018 Nov;103(11):e505-e509.

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Lo MC, Martens JH, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Zhang DE, van der Reijden BA, Khandanpour C. Haematologica. 2018 Sep;103(9):e395-e399.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J. Bone Marrow Transplant. 2018 May 4;54(1):44-52.

Structure-activity studies on N-substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T, Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R, Jung M.  J. Med. Chem. 2018 Jan 20; 144:52-67.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Bug G, Burchert A, Wagner EA, Kröger N, Berg T, Güller S, Metzelder SK, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann OG. . Leukemia. 2017 Nov; 31(11):2523-2525.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Mohr S*, Doebele C*, Comoglio F*, Berg T*, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T. Cancer Cell. 2017 Apr 10;31(4):549-562.e11. * denotes equal contribution

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia. Lindner S, Berg T, Riemann J, Ajib S, Jedlickova Z, Gueller S, Lang F, Martin H, Serve H, Bacigalupo A, Bug G. Ann Hematol. 2016 May;95(6):1023-5.

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. Leukemia. 2016 Feb;30(2):473-83.

MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F.  Exp Hematol. 2015 Oct;43(10):858-868.

Quantitative mass spectrometric profiling of cancer-cell proteomes derived from liquid and solid tumors.  Bohnenberger H, Ströbel P, Mohr S, Corso J, Berg T, Urlaub H, Lenz C, Serve H, Oellerich T. Quantitative mass spectrometric profiling of cancer-cell proteomes derived from liquid and solid tumors. J Vis Exp. 2015 Feb 27;(96):e52435.

Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Imren S, Heuser M, Gasparetto M, Beer PA, Norddahl GL, Xiang P, Chen L, Berg T, Rhyasen GW, Rosten P, Park G, Moon Y, Weng AP, Eaves CJ, Humphries RK.  Blood. 2014 Dec 4;124(24):3608-12.

A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.  Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, Lim E, Bilenky M, Mungall AJ, Oellerich T, Lee S, Lai CK, Umlandt P, Salmi A, Chang H, Yue L, Lai D, Cheng SW, Morin RD, Hirst M, Serve H, Marra MA, Morin GB, Gascoyne RD, Aparicio SA, Humphries RK. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood. 2014 Jun 19;123(25):3914-24.

β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Oellerich T, Oellerich MF, Engelke M, Münch S, Mohr S, Nimz M, Hsiao HH, Corso J, Zhang J, Bohnenberger H, Berg T, Rieger MA, Wienands J, Bug G, Brandts C, Urlaub H, Serve H. Blood. 2013 May 9;121(19):3889-99.

Polo-like kinases in AML. Berg T, Bug G, Ottmann OG, Strebhardt K. Expert Opin Investig Drugs. 2012 Aug;21(8):1069-74.

Functional role of BAALC in leukemogenesis. Heuser M*, Berg T*, Kuchenbauer F, Lai CK, Park G, Fung S, Lin G, Leung M, Krauter J, Ganser A, Humphries RK. Leukemia. 2012 Mar;26(3):532-6. * denotes equal contribution

Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, Kuchenbauer F, Park G, Hamwi I, Palmqvist L, Lai CK, Leung M, Lin G, Chaturvedi A, Thakur BK, Iwasaki M, Bilenky M, Thiessen N, Robertson G, Hirst M, Kent D, Wilson NK, Göttgens B, Eaves C, Cleary ML, Marra M, Ganser A, Humphries RK. Cancer Cell. 2011 Jul 12;20(1):39-52.

Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Rüschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Blood. 2011 Sep 22;118(12):3350-8.

The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M. Oncogene. 2011 Jul 7;30(27):3062-72.

Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.Duque-Afonso J, Solari L, Essig A, Berg T, Pahl HL, Lübbert M.  Br J Haematol. 2011 Jun;153(5):612-22.

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA.  Blood. 2011 Feb 24;117(8):2451-9.

Delineating domains and functions of NUP98 contributing to the leukemogenic activity of NUP98-HOX fusions. Yung E, Sekulovic S, Argiropoulos B, Lai CK, Leung M, Berg T, Vollett S, Chang VC, Wan A, Wong S, Humphries RK. Leuk Res. 2011 Apr;35(4):545-50.

Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D, Marmolejo L, Heuser M, Berg T, Copley M, Ruschmann J, Sekulovic S, Benz C, Kuroda E, Ho V, Antignano F, Halim T, Giambra V, Krystal G, Takei CJ, Weng AP, Piret J, Eaves C, Marra MA, Humphries RK, Hansen CL. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15443-8.

Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia. Heuser M, Park G, Moon Y, Berg T, Xiang P, Kuchenbauer F, Vollett S, Lai C, Humphries RK. Exp Hematol. 2010 Mar;38(3):174-9.

Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M.  Haematologica. 2008 Nov;93(11):1728-33.

Leukemia-targeting ligands isolated from phage-display peptide libraries. Jäger S, Jahnke A, Wilmes T, Adebahr S, Vögtle FN, Delima-Hahn E, Pfeifer D, Berg T, Lübbert M, Trepel M.  Leukemia. 2007 Mar;21(3):411-20.

Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lübbert M.  Leuk Res. 2007 Apr;31(4):497-506.

Comparison of tolerated and rejected islet grafts: a gene expression study. Berg T, Wu T, Levay-Young B, Heuss N, Pan Y, Kirchhof N, Sutherland DE, Hering BJ, Guo Z.  Cell Transplant. 2004;13(6):619-29.

Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. Fliegauf M, Stock M, Berg T, Lübbert M.  Oncogene. 2004 Dec 2;23(56):9070-81.